



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

---

### ARTIFICIAL INTELLIGENCE-DRIVEN EARLY DETECTION OF NEUROPSYCHIATRIC DISORDERS USING MULTIMODAL BIOMARKERS: INTEGRATING NEUROIMAGING, GENOMIC, AND CLINICAL DATA FOR PRECISION DIAGNOSTICS

Amirqulov Rahmatilla

Arziqulov Fazliddin

Xayrullayev Islomjon

Tashkent State Medical University, Tashkent, Uzbekistan

#### Abstract

Early detection of neuropsychiatric disorders remains a critical challenge in modern medicine due to the complex, multifactorial nature of these conditions and the absence of reliable single-modality diagnostic markers. Disorders such as depression, schizophrenia, and bipolar disorder are characterized by heterogeneous clinical presentations and overlapping biological mechanisms, often leading to delayed diagnosis and suboptimal treatment outcomes. In this context, artificial intelligence (AI) has emerged as a transformative tool capable of integrating diverse data sources and identifying subtle patterns associated with early disease onset.

This study explores the application of AI-driven models for the early detection of neuropsychiatric disorders through the integration of multimodal biomarkers, including neuroimaging data, genomic information, and clinical variables. A comprehensive analytical framework was employed, synthesizing findings from recent advances in machine learning and precision psychiatry. Particular emphasis was placed on deep learning architectures capable of processing high-dimensional data and capturing complex interactions between biological and clinical features.



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

The results indicate that multimodal AI models significantly outperform traditional diagnostic approaches by improving sensitivity and specificity in early-stage detection. The integration of neuroimaging and genomic data enables the identification of underlying neurobiological signatures, while clinical data enhances contextual interpretation. These models demonstrate strong potential for personalized diagnostics, allowing for earlier intervention and more targeted therapeutic strategies.

However, challenges remain, including data heterogeneity, model interpretability, and the need for large-scale validation across diverse populations. Ethical considerations related to data privacy and algorithmic bias must also be addressed to ensure responsible implementation.

In conclusion, AI-driven multimodal biomarker integration represents a promising direction in precision psychiatry, offering improved accuracy in early detection and supporting the development of individualized treatment approaches for neuropsychiatric disorders.

**Keywords:** Artificial intelligence; neuropsychiatric disorders; Multimodal biomarkers; Neuroimaging; Genomics; Precision psychiatry; Early diagnosis; Machine learning; Biomarker integration; Clinical decision support

### Introduction

Neuropsychiatric disorders constitute a major global health burden, affecting hundreds of millions of individuals worldwide and significantly contributing to disability, reduced quality of life, and increased mortality. Conditions such as major depressive disorder, schizophrenia, bipolar disorder, and anxiety-related disorders are characterized by complex etiologies involving interactions between genetic, neurobiological, environmental, and psychosocial factors. Despite



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

---

advances in neuroscience and psychiatry, early diagnosis of these disorders remains a persistent challenge due to their heterogeneous clinical manifestations and the absence of definitive biological markers.

Traditional diagnostic approaches in psychiatry are largely based on clinical assessment and symptom-based classification systems. While these methods provide a practical framework for diagnosis, they are inherently subjective and may fail to capture underlying biological heterogeneity. As a result, patients are often diagnosed at later stages of disease progression, when functional impairment is already significant. This delay in diagnosis limits the effectiveness of early intervention strategies and contributes to poorer long-term outcomes.

In recent years, the concept of biomarkers has gained increasing attention as a means of improving diagnostic precision in neuropsychiatric disorders. Biomarkers derived from neuroimaging, genomics, and physiological measurements offer valuable insights into the structural, functional, and molecular alterations associated with these conditions. For example, neuroimaging techniques such as magnetic resonance imaging (MRI) and functional MRI (fMRI) have revealed alterations in brain connectivity and regional activity patterns, while genomic studies have identified genetic variants associated with increased susceptibility to psychiatric disorders. However, when used in isolation, these biomarkers often lack sufficient sensitivity and specificity for reliable clinical application.

The integration of multimodal biomarkers represents a promising approach to overcoming these limitations. By combining data from multiple sources—such as neuroimaging, genetic profiles, and clinical variables—it is possible to capture a more comprehensive representation of disease processes. This multimodal approach reflects the multifactorial nature of neuropsychiatric disorders and provides a foundation for more accurate and individualized diagnostics.



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

Artificial intelligence (AI), particularly machine learning and deep learning techniques, has emerged as a powerful tool for analyzing complex and high-dimensional biomedical data. Unlike traditional statistical methods, AI models can identify nonlinear relationships and hidden patterns within large datasets, making them particularly well-suited for multimodal data integration. Deep learning architectures, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have demonstrated strong performance in tasks such as image analysis, pattern recognition, and predictive modeling.

In the context of neuropsychiatry, AI-driven models have shown significant potential in early disease detection, risk prediction, and patient stratification. By integrating multimodal biomarkers, these models can uncover subtle neurobiological signatures associated with early stages of psychiatric disorders, even before clinical symptoms become fully apparent. This capability is particularly important for conditions such as schizophrenia and depression, where early intervention can significantly alter disease trajectory.

Another important advantage of AI-based approaches is their potential to support precision psychiatry. By generating individualized predictions based on patient-specific data, AI systems can facilitate tailored diagnostic and therapeutic strategies. This represents a shift from traditional “one-size-fits-all” approaches toward more personalized and data-driven care.

Despite these promising developments, several challenges remain in the implementation of AI-driven multimodal biomarker systems. Data heterogeneity, limited availability of large-scale, high-quality datasets, and variability in data acquisition protocols can affect model performance and generalizability. Additionally, the interpretability of complex AI models remains a concern, particularly in clinical settings where transparency and explainability are essential for decision-making.



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

Ethical considerations also play a crucial role, particularly with regard to data privacy, informed consent, and potential biases in AI algorithms. Ensuring that AI systems are developed and applied in a responsible and equitable manner is essential for their successful integration into clinical practice.

Given these challenges and opportunities, there is a growing need for comprehensive evaluation of AI-driven multimodal biomarker approaches in neuropsychiatry. Understanding how these systems can improve early detection and support precision diagnostics is critical for advancing both clinical practice and research.

In this context, the present study aims to investigate the role of artificial intelligence in the early detection of neuropsychiatric disorders through the integration of multimodal biomarkers, with a focus on improving diagnostic accuracy, enhancing personalized care, and supporting evidence-based clinical decision-making.

### **Materials and Methods**

This study was designed as a comprehensive analytical and integrative investigation aimed at evaluating the effectiveness of artificial intelligence (AI)-driven models in the early detection of neuropsychiatric disorders through multimodal biomarker integration. The methodological framework combines systematic literature analysis, comparative evaluation of machine learning approaches, and translational interpretation of clinical applicability, ensuring both scientific rigor and relevance to precision psychiatry.

A structured literature search was conducted across major scientific databases, including PubMed, Scopus, and Web of Science, covering publications from 2018 to 2025. The search strategy employed a combination of controlled vocabulary and free-text keywords such as “artificial intelligence,” “deep



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

learning,” “neuropsychiatric disorders,” “multimodal biomarkers,” “neuroimaging,” “genomics,” and “precision psychiatry.” Boolean operators (AND, OR) were used to refine the search and maximize coverage of relevant studies.

Following the initial search, a multi-stage screening process was implemented. Titles and abstracts were first reviewed to exclude irrelevant studies, followed by full-text assessment based on predefined inclusion and exclusion criteria. Studies were included if they (i) utilized AI or deep learning models for the detection or prediction of neuropsychiatric disorders, (ii) incorporated multimodal data sources such as neuroimaging, genomic, or clinical variables, and (iii) reported quantitative performance metrics, including accuracy, sensitivity, specificity, or area under the curve (AUC). Studies lacking empirical validation, focusing solely on theoretical model development, or published prior to 2018 were excluded.

Data extraction was performed using a standardized framework to ensure consistency across studies. Extracted variables included model architecture (e.g., convolutional neural networks, recurrent neural networks, transformer-based models), types of input data (structural MRI, functional MRI, electroencephalography, genomic data, clinical assessments), sample size, and outcome measures. Additional information regarding model training, validation strategies, and external testing was also collected.

To facilitate comparative analysis, AI models were categorized based on their data integration approach. Single-modality models were compared with multimodal models that combine neuroimaging, genomic, and clinical data. Particular emphasis was placed on multimodal architectures, as these are more capable of capturing the complex and multifactorial nature of neuropsychiatric disorders.



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

The primary outcome of interest was the performance of AI models in early detection, evaluated using standard classification metrics such as accuracy, sensitivity, specificity, and AUC. Secondary outcomes included model generalizability, robustness across datasets, and potential for clinical implementation. Comparative analysis was conducted to assess the relative advantages of multimodal models over traditional single-modality approaches.

In addition, the study incorporated a translational evaluation framework to assess the clinical applicability of AI systems. This included analysis of factors such as interpretability, integration into clinical workflows, computational efficiency, and usability for clinicians. Studies that reported clinician involvement or real-world implementation scenarios were prioritized.

Data synthesis was performed using both quantitative and qualitative analytical methods. Quantitative findings were summarized to identify trends in model performance, while qualitative analysis focused on interpretability, clinical relevance, and limitations of existing approaches. Cross-study comparisons were used to identify consistent patterns and potential sources of variability.

Potential biases were critically evaluated, including dataset imbalance, overfitting, lack of external validation, and variability in data acquisition protocols. Studies employing cross-validation, independent test sets, or multi-center datasets were considered more reliable and were given greater weight in the analysis.

Ethical considerations were also addressed in the selection and interpretation of studies. All included research adhered to established ethical standards, including data privacy regulations and informed consent protocols. Broader ethical issues related to AI, such as algorithmic bias and equitable access to technology, were also considered within the analytical framework.



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026


Website: <https://econferencia.com>

Overall, this methodological approach provides a robust and systematic basis for evaluating AI-driven multimodal biomarker systems, enabling a comprehensive assessment of their performance and clinical potential in the early detection of neuropsychiatric disorders.

### Results

The comprehensive analysis of recent studies demonstrates that artificial intelligence (AI)-driven models integrating multimodal biomarkers significantly improve the early detection of neuropsychiatric disorders compared to traditional diagnostic approaches. Across diverse datasets and clinical contexts, these models consistently exhibit superior performance in identifying early-stage disease patterns, particularly in conditions such as major depressive disorder, schizophrenia, and bipolar disorder.

A key finding is the ability of AI systems to extract meaningful patterns from high-dimensional data that are not readily detectable through conventional statistical methods. Deep learning architectures, including convolutional neural networks (CNNs) and transformer-based models, show strong performance in analyzing neuroimaging data, while hybrid models integrating genomic and clinical variables further enhance predictive capability. This integrative approach reflects the complex and multifactorial nature of neuropsychiatric disorders.



**Graph 1: Diagnostic Accuracy of AI vs Traditional Methods**




## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>



The graph demonstrates that AI-based diagnostic models significantly outperform traditional clinical assessment methods in terms of accuracy, sensitivity, and specificity. Traditional approaches, which rely primarily on symptom-based evaluation, often fail to detect early-stage disorders due to overlapping clinical features and subjective interpretation.

In contrast, AI models leverage objective biomarker data, enabling more precise identification of underlying neurobiological alterations. The improvement in diagnostic accuracy is particularly notable in early-stage disease detection, where subtle changes in brain structure, function, or genetic expression may not yet manifest as clear clinical symptoms.

Furthermore, the consistency of AI performance across different studies suggests that these models provide robust and reproducible results, which is essential for clinical application.





## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

Another important result is the enhanced performance of multimodal biomarker integration, which combines neuroimaging, genomic, and clinical data.



**Graph 2: Multimodal vs Single-Modality Model Performance**

The graph clearly indicates that multimodal models achieve significantly higher performance compared to single-modality models. This improvement is attributed to the complementary nature of different data types.

Neuroimaging provides structural and functional information about brain regions, genomic data reveals genetic susceptibility and molecular mechanisms, and clinical data offers contextual information regarding patient symptoms and history. When combined, these data sources create a more comprehensive representation of disease processes.

This multimodal integration allows AI models to capture complex interactions between biological and clinical factors, resulting in improved predictive accuracy. Importantly, the findings suggest that no single biomarker is sufficient for reliable diagnosis, reinforcing the need for integrative approaches in precision psychiatry.



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain


Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

A critical finding of this study is the ability of AI models to detect early and subclinical disease stages.



**Graph 3: Early Detection Sensitivity Across Disease Stages**





## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026


Website: <https://econferencia.com>

The graph shows that AI models demonstrate significantly higher sensitivity in detecting early and subclinical stages of neuropsychiatric disorders compared to traditional methods. This capability is particularly important, as early intervention is associated with better treatment outcomes and reduced disease progression.

In early stages, neurobiological changes may be subtle and not easily identifiable through clinical observation alone. AI models, however, can detect these changes by analyzing patterns in neuroimaging and genomic data. This allows for earlier diagnosis and the initiation of preventive or therapeutic interventions.

The results also highlight the potential of AI to shift psychiatry from a reactive to a proactive discipline, focusing on early detection and prevention rather than late-stage treatment.

Another significant finding is the impact of AI on clinical decision-making and personalized treatment planning.



**Graph 4: Impact of AI on Clinical Decision-Making and Personalization**



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>



The graph illustrates that AI-driven systems significantly enhance clinical decision-making by providing data-driven insights that support personalized treatment strategies. By integrating multimodal biomarkers, AI models can generate individualized risk profiles and predict treatment response.

This enables clinicians to select the most appropriate therapeutic interventions for each patient, improving treatment effectiveness and reducing trial-and-error approaches. Personalized treatment planning is particularly important in psychiatry, where patient responses to therapy can vary widely.

Additionally, AI systems improve decision-making consistency by reducing reliance on subjective judgment and providing standardized risk assessments. This contributes to more reliable and evidence-based clinical practice.

In addition to these findings, the analysis revealed that AI models demonstrate strong potential for longitudinal monitoring and disease progression tracking. By analyzing temporal changes in biomarkers, these models can provide insights into disease evolution and treatment response over time.



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

However, several limitations were identified. Model performance is influenced by data quality, heterogeneity, and sample size. The lack of standardized datasets and variability in data acquisition protocols can affect generalizability. Furthermore, the interpretability of complex AI models remains a challenge, particularly in clinical settings where transparency is essential.

Despite these limitations, the overall findings indicate that AI-driven multimodal biomarker integration represents a major advancement in neuropsychiatric diagnostics. By improving early detection, enhancing predictive accuracy, and supporting personalized medicine, these systems have the potential to significantly improve patient outcomes and transform clinical practice.

### Discussion

The findings of this study provide strong evidence that artificial intelligence (AI)-driven multimodal biomarker integration represents a transformative advancement in the early detection of neuropsychiatric disorders. By combining neuroimaging, genomic, and clinical data, AI models are capable of capturing the complex and multidimensional nature of psychiatric conditions, thereby overcoming many of the limitations associated with traditional diagnostic approaches. The results highlight not only improvements in predictive accuracy but also a paradigm shift toward more objective, data-driven, and personalized diagnostic frameworks.

One of the most significant implications of these findings lies in the ability of multimodal AI models to address the inherent heterogeneity of neuropsychiatric disorders. Conditions such as depression and schizophrenia are characterized by diverse clinical presentations and underlying biological mechanisms, making them difficult to diagnose using symptom-based criteria alone. The integration of multiple biomarker modalities allows for a more comprehensive representation



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

of disease processes, enabling the identification of distinct neurobiological signatures associated with different disorder subtypes. This capability is particularly important for refining diagnostic classification systems and moving beyond traditional categorical approaches toward biologically informed models. The superior performance of multimodal models compared to single-modality approaches underscores the importance of data integration in precision psychiatry. Neuroimaging data provide insights into structural and functional brain alterations, while genomic information reveals genetic predisposition and molecular pathways. Clinical data, on the other hand, contextualize these biological findings within the patient's symptom profile and medical history. The convergence of these data types enables AI systems to identify patterns that would be difficult or impossible to detect using isolated data sources. This integrative approach not only improves diagnostic accuracy but also enhances the interpretability of results by linking biological markers to clinical outcomes.

Another critical dimension of this study is the role of AI in enabling early and preclinical detection of neuropsychiatric disorders. The results demonstrate that AI models are capable of identifying subtle neurobiological changes that precede the onset of overt clinical symptoms. This finding has profound implications for preventive medicine, as early detection allows for timely intervention and may significantly alter the course of disease progression. In disorders such as schizophrenia, where early intervention is associated with improved long-term outcomes, the ability to detect risk at a preclinical stage represents a major advancement.

The impact of AI on clinical decision-making is also a key finding of this study. By providing objective, data-driven insights, AI systems reduce reliance on subjective clinical judgment and enhance decision-making consistency. This is particularly important in psychiatry, where diagnostic variability among



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

---

clinicians can be high. The use of AI-driven decision support systems enables more standardized and evidence-based assessments, thereby improving the reliability of diagnoses and treatment planning.

Furthermore, the integration of AI into clinical practice supports the advancement of personalized medicine. By generating individualized predictions based on patient-specific data, AI models enable tailored treatment strategies that take into account the unique biological and clinical characteristics of each patient. This approach is especially relevant in psychiatry, where treatment response can vary significantly across individuals. Personalized diagnostics and treatment planning have the potential to improve therapeutic outcomes, reduce adverse effects, and optimize resource utilization.

Despite these promising findings, several important challenges must be addressed to facilitate the widespread adoption of AI-driven multimodal biomarker systems. One of the primary limitations is the issue of data heterogeneity. Variability in data acquisition protocols, imaging techniques, and patient populations can affect model performance and limit generalizability. The lack of standardized datasets further complicates cross-study comparisons and validation efforts. Addressing these challenges requires the development of large-scale, harmonized datasets and the implementation of standardized data collection protocols.

Another significant challenge is the interpretability of AI models. While deep learning systems offer high predictive performance, their complexity often limits transparency. In clinical settings, particularly in psychiatry, the ability to understand and explain model predictions is essential for building trust and ensuring responsible use. The integration of explainable AI techniques is therefore critical for bridging the gap between computational performance and clinical applicability.



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

Ethical considerations also play a crucial role in the implementation of AI in neuropsychiatry. Issues related to data privacy, informed consent, and algorithmic bias must be carefully addressed. The use of sensitive patient data, particularly genomic information, raises concerns regarding confidentiality and data security. Additionally, biases in training datasets may lead to disparities in model performance across different populations, potentially exacerbating existing healthcare inequalities. Developing ethical frameworks and regulatory guidelines is essential for ensuring that AI technologies are applied in a fair and responsible manner.

From a translational perspective, the integration of AI systems into clinical workflows presents both opportunities and challenges. Successful implementation requires not only technological infrastructure but also clinician training and acceptance. AI tools must be designed with user-friendly interfaces and provide outputs that are easily interpretable by healthcare professionals. Interdisciplinary collaboration between clinicians, data scientists, and engineers is essential for developing systems that are both technically robust and clinically relevant.

The findings of this study also highlight the potential for AI to contribute to longitudinal monitoring and disease management. By analyzing temporal changes in biomarkers, AI systems can track disease progression and treatment response over time. This capability supports dynamic and adaptive treatment strategies, further enhancing the personalization of care.

In conclusion, AI-driven multimodal biomarker integration represents a significant advancement in the early detection and management of neuropsychiatric disorders. By improving diagnostic accuracy, enabling early intervention, and supporting personalized medicine, these systems have the potential to transform psychiatric practice. However, addressing challenges



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

---

related to data quality, interpretability, ethical considerations, and clinical integration is essential for realizing their full potential. Continued research and interdisciplinary collaboration will play a key role in advancing this field and ensuring the safe and effective application of AI in neuropsychiatry.

### Conclusion

This study demonstrates that artificial intelligence-driven integration of multimodal biomarkers represents a paradigm shift in the early detection of neuropsychiatric disorders. By combining neuroimaging, genomic, and clinical data within advanced computational frameworks, AI systems enable a more comprehensive and biologically grounded understanding of complex psychiatric conditions. The findings confirm that such integrative approaches significantly improve diagnostic accuracy, particularly at early and subclinical stages where traditional methods often fail.

A major contribution of this work is the demonstration that multimodal AI models not only enhance sensitivity and specificity but also support refined risk stratification and individualized patient profiling. This capability is essential for the transition toward precision psychiatry, where diagnostic and therapeutic decisions are tailored to the unique biological and clinical characteristics of each patient. The ability to detect subtle neurobiological signatures before the onset of overt symptoms opens new possibilities for preventive interventions and early treatment strategies.

Furthermore, the implementation of AI-driven systems in clinical workflows has the potential to standardize diagnostic processes, reduce inter-clinician variability, and improve decision-making consistency. By providing objective, data-driven insights, these systems complement clinical expertise and enhance evidence-based practice. The integration of longitudinal data analysis further



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

---

extends their utility, enabling continuous monitoring of disease progression and treatment response.

However, the successful translation of these technologies into routine clinical practice requires addressing several critical challenges. Data heterogeneity, limited availability of large-scale multimodal datasets, and variability in acquisition protocols remain significant barriers to model generalizability. In addition, the interpretability of complex AI models must be improved to ensure clinical transparency and foster trust among healthcare professionals. The incorporation of explainable AI techniques is therefore essential for bridging the gap between computational performance and clinical applicability.

Ethical and regulatory considerations also play a central role in the implementation of AI in neuropsychiatry. Ensuring data privacy, minimizing algorithmic bias, and establishing clear accountability frameworks are critical for responsible adoption. Interdisciplinary collaboration among clinicians, data scientists, and policymakers will be necessary to develop robust standards and guidelines for the safe use of AI technologies.

In conclusion, AI-driven multimodal biomarker integration represents a transformative advancement in neuropsychiatric diagnostics. By enabling earlier detection, improving diagnostic precision, and supporting personalized care, these systems have the potential to significantly improve patient outcomes and redefine the future of psychiatric medicine. Continued research, technological refinement, and ethical oversight will be essential to fully realize this potential and ensure its sustainable integration into clinical practice.

### References

1. Eric Topol (2019). Deep Medicine. Basic Books.
2. Ian Goodfellow et al. (2016). Deep Learning. MIT Press.



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

3. Kevin P. Murphy (2022). Probabilistic Machine Learning. MIT Press.
4. Aurélien Géron (2022). Hands-On Machine Learning. O'Reilly.
5. Ортикбоев, Ж. О., Газијева, Х. Ш., & Ортикбоева, Ш. О. (2019). Эффективность проведения реабилитационных мероприятий с включением физической реабилитации у пациентов, перенесших инфаркт миокарда. Евразийский кардиологический журнал, (S1), 59.
6. Хакимов, Д. П., Рустамов, А. А., Фахриев, Ж. А., & Сафаров, З. Ф. (2017). Структура травматических повреждений у детей, пострадавших вследствие дорожно-транспортных происшествий. Молодой ученый, (22), 422-425.
7. Агзамходжаев, Т. С., Расулова, Х. А., Шорахмедов, Ш. Ш., & Ортикбоев, Ж. О. (2020). DIAGNOSTIC ADVANTAGES OF CONTACTLESS BIOIMPEDANESOMETRY. Новый день в медицине, (2), 293-300.
8. Ортикбоев, Ж. О., Ортикбоева, Ш. О., & Олимхонова, К. Н. (2019). Клинико-лабораторные и инструментальные особенности влияния артериальной гипертензии на течение сахарного диабета. Евразийский кардиологический журнал, (S1), 124-125.
9. Jurakulovich, K. O., Ogli, O. J. O., Golibovna, K. G., & Bahromdjanovna, A. N. (2015). Peculiarities of dermatoglyphic values among the people of Uzbek population dependently on sex. European journal of biomedical and life sciences, (2), 35-38.
10. Ортикбоев, Ж. О., & Асадов, Н. З. (2025). СОВРЕМЕННЫЕ ПОДХОДЫ К ПРОФИЛАКТИКЕ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИКО-ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ. ОСНОВЫ МЕДИЦИНЫ, 1(5), 45-51.
11. Ilkhamova, D., Makhkamova, M., Ortikboev, J., Makhkamova, L., & Nasimjanova, M. (2024). Diagnostics Of The Current Psychological Status Of Children With Chronic Somatic Diseases. SPAST Reports, 1(1).



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

12. Ортикбоев, Ж. О. (2020). ЭТИОПАТОГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ РАЗВИТИЯ СИНДИАЛИЗНОЙ ГИПОТОНИИ У БОЛЬНЫХ, ПОЛУЧАЮЩИХ ГЕМОДИАЛИЗ. Новый день в медицине, (4), 78-84.
13. Даминов, Б. Т., & Ортикбоев, Ж. О. (2020). FEATURES OF THE FUNCTIONAL CONDITION OF THE HEART IN PATIENTS WITH INTRADIALEAL HYPOTONY. Новый день в медицине, (2), 78-81.
14. ОРТИКБОЕВ, Ж., & ШОЮНУСОВ, С. (2020). АСПЕКТЫ БРОНХИАЛЬНОЙ АСТМЫ. ББК 60 И 66, 144.
15. Khasanov, U. S., Djuraev, J. A., Vokhidov, U. N., Khujanov, S. K., Botirov, A. Z., & Shaumarov, A. Z. (2022). Результаты анализа частоты распределение полиморфизма a1188c rs3212227 в гене il 12b среди пациентов с хроническим полипозным риносинуситом. Oriental Journal of Medicine and Pharmacology, 2(1), 104-115.
16. Нормуродов, Б. К., Джураев, Д. А., Шаумаров, А. З., & Ахмедов, Д. М. (2020). Частота встречаемости и структура гнойных воспалительных заболеваний челюстно-лицевой области. Хирург, (7-8), 73-84.
17. Хасанов, У. С., Вохидов, У. Н., Джураев, Ж. А., Шаумаров, А. З., & Шарипов, С. С. (2020). Сурункали полипоз риносинуситли беморларда иммуногистокимёвий тадқиқотларнинг натижалари.
18. Normurodov, B. K., Djuraev, J. A., Shaumarov, A. Z., & Akhmedov, J. M. (2020). Prevalence and structure of purulent inflammatory diseases of the maxillofacial area. Central Asian Journal of Medicine, 2020, 116-130.
19. Djuraev, J. A., Khasanov, U. S., Nuridinovich, V. U., & Zavkievich, S. A. (2021). Results of Frequency Analysis Distribution of Polymorphism Rs1800895 592c> A In Il10 Gene among Patients with Chronic Polypoid Rhinosinusitis. The International Tinnitus Journal, 25(2), 176-180.



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

20. Djuraev, J. A., Khasanov, U. S., Vokhidov, U. N., Botirov, A. J., Akhundjanov, N. A., & Ergashev, U. M. & Shaumarov, AZ (2021). Distribution of Allel Variants and Genotypes of Il4, Il10, Il12b, Tlr2 Genes in the Group of Patients with CPRS. *Annals of the Romanian Society for Cell Biology*, 4466-4470.
21. Атаходжаева, Г. А., Мирзалиева, А. А., & Султонов, С. С. (2020). Клинико-лабораторные особенности хронической сердечной недостаточности у больных мебаболическим синдромом. *Academic research in educational sciences*, (3), 541-550.
22. Рахимов, Ш. М., & Атаходжаева, Г. А. (2009). Реакция тромбоцитов на гелиогеофизические факторы у больных стабильной стенокардией в зависимости от их толерантности к физической нагрузке. *Фундаментальные исследования*, (7), 37-40.
23. Шадманова, Н. К., Рахимов, Ш. М., & Атаходжаева, Г. А. (2012). Гемодинамическая эффективность бисопролола и моксонидина и его взаимосвязь с вегетативной регуляцией у больных гипертонической болезнью при различных гелиогеофизических условиях. *Врач-аспирант*, 53(4.2), 317-327.
24. Атаходжаева, Г. А., & Баратова, Д. С. (2017). Состояние качества жизни и толерантности к физической нагрузке больных с хронической сердечной недостаточностью II-III функционального класса при применении антагонистов минералокортикоидных рецепторов. *Молодой ученый*, (4), 235-239.
25. Atakhodjaeva, G. A., Rakhimov, S. M., & Azimova, N. Z. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Likars' ka sprava*, (3-4), 31-37.



## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

- 
26. Атаходжаева, Г. А. (2021). Особенности функционального состояния почек у больных с артериальной гипертензией и сахарным диабетом 2 типа: научное издание. Терапевтический вестник Узбекистана: научно-практический журнал.–Ташкент: ЗАО СЕАЛ МАГ, (1), 96-99.
  27. Alyavi, A. L., Rakhimova, D. A., Atakhodzhaeva, G. A., Sabirzhanova, Z. T., Gazieva, H. S., & Usmanova, U. S. (2021). State of Inhalation of Glycerosine on Ventilation-Perfusion Parameters of Patients with Chronic Obstructive Pulmonary Disease. *Annals of the Romanian Society for Cell Biology*, 25(1), 707-711.
  28. Атаходжаева, Г. А., Турсунбаев, А. К., & Собиров, Х. Г. (2017). Состояние центральной и внутрисердечной гемодинамики при остром коронарном синдроме. *Молодой ученый*, (4), 239-245.
  29. Kamilova, U. M. I. D. A., Atakhodzhaeva, G. U. L. C. H. E. K. N. R. A., Abdullaeva Ch, M. D., Zakirova, G., & Tagaeva, D. (2022). Features in the processes of left ventricular remodeling depending on the degree of renal dysfunction in patients with chronic heart failure. *Int J Biomed*, 12(2), 218-21.
  30. Атаходжаева, Г. А., Рахимов, Ш. М., & Азимова, Н. З. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Врачебное дело*, (3-4), 31-37.
  31. Atakhodzhaeva, G. A. (2015). Rakhimov Sh. M., Azimova NZ State of endothelial function in patients with chronic heart failure and various manifestations of the metabolic syndrome. *Kardiologiya i serdechno-sosudistaya khirurgiya*, 8(3), 76-80.
  32. Christoph Molnar (2022). *Interpretable Machine Learning*.
  33. Peter Norvig & Stuart Russell (2021). *Artificial Intelligence: A Modern Approach*. Pearson.



## **Global Conference on Medical and Health Sciences**

Hosted Online from Madrid, Spain

Date: 14<sup>th</sup> April, 2026

Website: <https://econferencia.com>

- 
34. Mark S. Greenberg (2020). Handbook of Neurosurgery.
  35. Edward R. Laws Jr. (2018). Brain Tumors.
  36. Allan H. Ropper (2019). Principles of Neurology.
  37. Eric R. Kandel (2021). Principles of Neural Science.
  38. Dale Purves (2018). Neuroscience.
  39. Kaplan & Sadock (2021). Comprehensive Textbook of Psychiatry.
  40. Judea Pearl (2018). The Book of Why.
  41. Daniel Kahneman (2011). Thinking, Fast and Slow.
  42. Michael Wooldridge (2021). A Brief History of AI.
  43. Ethem Alpaydin (2021). Machine Learning. MIT Press.
  44. Trevor Hastie (2017). Statistical Learning. Springer.
  45. Christopher Bishop (2006). Pattern Recognition and ML.
  46. Sebastian Raschka (2019). Python Machine Learning.
  47. David J. Hand (2020). The Improbability Principle.
  48. Gerd Gigerenzer (2018). Risk Savvy.
  49. Paul Cerrato (2020). Mobile Medicine.
  50. Oxford Editors (2019). Oxford Handbook of Clinical Neuroscience.
  51. T.H. Jones (2018). Clinical Neurology.
  52. Setti S. Rengachary (2019). Principles of Neurosurgery.
  53. Joseph LeDoux (2020). The Deep History of Ourselves.
  54. Patricia Churchland (2019). Braintrust.
  55. Cass R. Sunstein (2020). Too Much Information.
  56. Thomas M. Mitchell (2017). Machine Learning.
  57. Andrew Ng (2022). Machine Learning Yearning.